Status:
COMPLETED
Glucocorticoid-induced Osteopenia in Children
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Crohn's Disease
Nephrotic Syndrome
Eligibility:
All Genders
5-21 years
Brief Summary
The purpose of this study is to characterize the skeletal deficits and risk factors for impaired skeletal development in children requiring glucocorticoid therapy. We will compare the bone health of ...
Detailed Description
Prednisone, a glucocorticoid medication, is widely used for many pediatric disorders. Studies have shown that this drug decreases bone formation, decreasing bone density and bone thickness in children...
Eligibility Criteria
Inclusion
- ages 5-21
- clinical and pathological diagnosis of Crohn's Disease within the last 2 years
- clinical diagnosis of nephrotic syndrome and taking corticosteroids within the last year
- normal renal function GFR\>75 ml/min/1.73m2
- healthy controls
Exclusion
- other major medical conditions affecting growth and/or bone health
- significant cognitive or developmental disorders (if child is unable to cooperate sufficiently)
- nonambulatory
Key Trial Info
Start Date :
November 1 2001
Trial Type :
OBSERVATIONAL
End Date :
April 1 2006
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT00289328
Start Date
November 1 2001
End Date
April 1 2006
Last Update
March 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19096